Venoruton® (Venoruton®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Similar drugsTo uncover
Dosage form: & nbspgel for external use
Composition:

1 g of gel contains 20 mg of the active substance (2%)

Active substance:

hydroxyethylrutosides 20 mg.

Excipients:

carbomer 4.00 mg, sodium hydroxide, solution 30% (by weight) 4.00 mg, disodium edetate 0.5 mg, benzalkonium chloride 0.05 mg, water purified to 1000 mg.

Description:Homogeneous, transparent, sometimes slightly opalescent gel of golden yellow color with practically no odor.
Pharmacotherapeutic group:Angioprotective agent
ATX: & nbsp
  • Rutozid
    • Pharmacodynamics:

    Angioprotective agent, a derivative of routine. Acts mainly on capillaries and veins. Strengthens the walls of blood vessels, improves microcirculation.

    With chronic venous insufficiency, Venoruton ® gel reduces the severity of edema, pain, seizures, trophic disorders, varicose ulcers, as well as the severity of other symptoms associated with chronic venous insufficiency of the lower extremities or traumatic injury. The drug has an anti-inflammatory effect, suppresses aggregation and increases the degree of deformability of erythrocytes.

    Reduces the gaps between endothelial cells by modifying the fibrous matrix located between endothelial cells.

    Venoruton® gel for external use is a water-based gel that does not contain alcohol.It is easily absorbed, odorless and leaves no greasy stains.

    Pharmacokinetics:

    After gel application the active substances quickly penetrate the epidermal barrier. After 30 minutes they are found in the dermis, and after 2-5 hours - in the subcutaneous fatty tissue.

    Indications:

    Chronic venous insufficiency with symptoms such as pain and swelling, including prolonged, more than 6 hours of air travel, pain after sclerosing therapy.

    Injuries (without compromising the integrity of the skin) with painful edematous syndrome: sprains, bruises of muscles and ligaments.
    Contraindications:

    Hypersensitivity to rutozides or other components. Pregnancy (first trimester).

    Venoruton® It is not recommended for use in children under the age of 18 due to lack of medical experience.

    Pregnancy and lactation:

    In experimental studies, there were no teratogenic or other adverse effects on the fetus and the baby during breastfeeding.

    The appointment of Venoruton® is possible in the II and III trimesters of pregnancy and during lactation, when the expected benefit for the mother from its use exceeds the possible risk to the fetus.
    Dosing and Administration:

    Outwardly. The drug is applied to the skin 2 times a day and rubbed with light massage until the skin becomes dry. If necessary, can be used under occlusive dressings.

    The maximum course of taking the drug without a break is 4 weeks.

    Side effects:

    Allergic reactions (cutaneous), local irritant effect. Symptoms of adverse reactions disappear after discontinuation of the drug.

    If any of the side effects listed in the manual are aggravated, or if you notice any other side effects not listed in the instructions, tell your doctor.
    Overdose:

    Clinical manifestations of an overdose of the gel for external use of Venoruton® are not described.

    Interaction:

    There are no data on the interaction of rutosides with other drugs.

    Special instructions:

    If the severity of the symptoms of the disease does not decrease during the period of the drug use, you should consult a doctor. Do not take the drug inside.

    The use of the drug in children has not been studied.

    The gel contains benzalkonium chloride, having a locally irritating effect.
    Effect on the ability to drive transp. cf. and fur:Does not affect.
    Form release / dosage:

    Gel for external use 2%.

    Packaging:For 40 g or 100 g of the preparation in an aluminum tube with an epoxy-phenolic resin-based inner coating, with a protective aluminum membrane, with a screw-on polyethylene lid provided with a protrusion for perforating the membrane. The tube together with the instruction for use is placed in a cardboard box.
    Storage conditions:

    At a temperature not exceeding 30 ° C in a place inaccessible to children.

    Shelf life:3 years.
    The drug should not be used after the expiry date indicated on the package.
    Terms of leave from pharmacies:Without recipe
    Registration number:P N008948 / 02
    Date of registration:05.07.2010 / 25.04.2016
    Expiration Date:Unlimited
    The owner of the registration certificate:GlaxoSmithKline Helsker, ZAO GlaxoSmithKline Helsker, ZAO Russia
    Manufacturer: & nbsp
    Representation: & nbspGlaxoSmithKline Helsker GlaxoSmithKline Helsker United Kingdom
    Information update date: & nbsp25.01.2017
    Illustrated instructions
      Instructions
      Up